Aligos Therapeutics Stock Performance
| ALGS Stock | USD 9.28 0.16 1.75% |
On a scale of 0 to 100, Aligos Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of 3.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aligos Therapeutics will likely underperform. Please check Aligos Therapeutics' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Aligos Therapeutics' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Aligos Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, Aligos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 135.8 M | |
| Total Cashflows From Investing Activities | -18.3 M |
Aligos Therapeutics Relative Risk vs. Return Landscape
If you would invest 583.00 in Aligos Therapeutics on April 24, 2025 and sell it today you would earn a total of 345.00 from holding Aligos Therapeutics or generate 59.18% return on investment over 90 days. Aligos Therapeutics is currently generating 0.9934% in daily expected returns and assumes 7.1688% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Aligos, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aligos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aligos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aligos Therapeutics, and traders can use it to determine the average amount a Aligos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1386
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALGS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.17 actual daily | 64 64% of assets are less volatile |
Expected Return
| 0.99 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Aligos Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aligos Therapeutics by adding it to a well-diversified portfolio.
Aligos Therapeutics Fundamentals Growth
Aligos Stock prices reflect investors' perceptions of the future prospects and financial health of Aligos Therapeutics, and Aligos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aligos Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (61.87) % | ||||
| Current Valuation | (74.22 M) | ||||
| Shares Outstanding | 5.31 M | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 17.05 X | ||||
| Revenue | 3.94 M | ||||
| EBITDA | (89.15 M) | ||||
| Cash And Equivalents | 159.34 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 8.38 M | ||||
| Debt To Equity | 0.1 % | ||||
| Book Value Per Share | 19.04 X | ||||
| Cash Flow From Operations | (80.74 M) | ||||
| Earnings Per Share | (17.47) X | ||||
| Total Asset | 70.09 M | ||||
| Retained Earnings | (618.01 M) | ||||
About Aligos Therapeutics Performance
Assessing Aligos Therapeutics' fundamental ratios provides investors with valuable insights into Aligos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aligos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about Aligos Therapeutics performance evaluation
Checking the ongoing alerts about Aligos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aligos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aligos Therapeutics is way too risky over 90 days horizon | |
| Aligos Therapeutics appears to be risky and price may revert if volatility continues | |
| Aligos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.14 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Aligos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aligos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aligos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aligos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aligos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aligos Therapeutics' stock. These opinions can provide insight into Aligos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.